Vor Biopharma Inc. Common Stock
VOR
VOR: Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
moreShow VOR Financials
Recent trades of VOR by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by VOR's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Genetically engineered hematopoietic stem cells and uses thereof Feb. 07, 2023
-
Patent Title: Genetically engineered hematopoietic stem cells and uses thereof Jan. 24, 2023
-
Patent Title: Genetically engineered hematopoietic stem cells and uses thereof Oct. 11, 2022
-
Patent Title: Genetically engineered hematopoietic stem cells and uses thereof Jul. 19, 2022
-
Patent Title: Genetically engineered hematopoietic stem cells and uses thereof Jul. 12, 2022
-
Patent Title: Genetically engineered hematopoietic stem cells and uses thereof Feb. 23, 2021
Federal grants, loans, and purchases
Followers on VOR's company Twitter account
Number of mentions of VOR in WallStreetBets Daily Discussion
Recent insights relating to VOR
Recent picks made for VOR stock on CNBC
ETFs with the largest estimated holdings in VOR
Flights by private jets registered to VOR